following an abbreviated submission:
bismuth subcitrate potassium/ metronidazole/ tetracycline (Pylera®) is accepted for restricted use within NHSScotland.
Indication under review: In combination with omeprazole, for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers.
SMC restriction: restricted to use in accordance with clinical guidelines for the eradication of H. pylori.
Pylera® is a new combination medicine of existing medicines, with limited net budget impact.
Download detailed advice243KB (PDF)
Medicine details
- Medicine name:
- bismuth subcitrate potassium/metronidazole/tetracycline hydrochloride (Pylera)
- SMC ID:
- SMC2701
- Indication:
In combination with omeprazole, for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers.
- Pharmaceutical company
- Flynn Pharma Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 11 November 2024